ADA and inflammatory bowel disease: All ADA positive patients (9% of study population, all with IBD) had significantly lower IFX trough levels than patients without ADAs, putting them at increased risk for therapeutic failure and increased risk of infusion reactions to IFX, which represents one of the only two biological agents approved for pediatric IBD.